President and Chief Executive Officer
Alicia Secor joined Juniper Pharmaceuticals as Chief Executive Officer in August 2016 and serves as a Director of the Company. Ms. Secor brings more than 25 years of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas.
Ms. Secor joined Juniper from Zafgen, Inc., where she was Chief Commercial Officer and played a key role in advancing the company to a Phase 3 pre-commercialization status. Previously, Ms. Secor served as Senior Vice President and Chief Operating Officer at Synagev BioPhamra Corp, and spent 15 years at Genzyme Corporation in diverse leadership roles, most recently as the Global General Manager for the Metabolic Disease Business. During her tenure at Genzyme, Ms. Secor led fully integrated businesses, successfully launching products and achieving sustained revenue growth. Ms. Secor spearheaded several strategic transactions and built high performance teams, resulting in consistent growth and profitability across multiple Genzyme businesses including biomaterials, surgical devices, and injectable therapeutics. Prior to Genzyme, Ms. Secor held positions at Alkermes, Inc. in business development, and at Centocor, Inc. (a Johnson & Johnson Company) in clinical and commercial operations. She began her career at Pfizer Inc. as a hospital-based sales representative. Ms. Secor also currently serves as a member of the Board of Directors for the Foundation for Prader-Willi Research.
Ms. Secor received an M.B.A. from Northeastern University, and a B.S. in Healthcare Administration from the University of New Hampshire.